Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Chlorotrianisene

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)

TACE first ,and more TACE could be performed when it is necessary.

TACE

Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE

Tilelizumab

Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE

Jun-hui Sun, MD,PH.D

Tong-yin Zhu, MD

According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study

1-year survival rate assessed by Kaplan-Meier analysis

Time to progression assessed by independent radiologic review according to mRECIST criteria

Progression free survival assessed by independent radiologic review according to mRECIST criteria

Objective response rate assessed by independent radiologic review according to mRECIST criteria

Disease control rate assessed by independent radiologic review according to mRECIST criteria

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC	NCT04992143	BCLC Stage C He...	TACE Tilelizumab Sorafenib	18 Years -	First Affiliated Hospital of Zhejiang University
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC	NCT04992143	BCLC Stage C He...	TACE Tilelizumab Sorafenib	18 Years -	First Affiliated Hospital of Zhejiang University

Spots Global Cancer Trial Database for bclc stage c

Every month we try and update this database with for bclc stage c cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.